A COMPARATIVE-STUDY OF TRANSURETHRAL RESECTION OF THE PROSTATE USING A MODIFIED ELECTRO-VAPORIZING LOOP AND TRANSURETHRAL LASER VAPORIZATION OF THE PROSTATE
Sa. Kaplan et Ae. Te, A COMPARATIVE-STUDY OF TRANSURETHRAL RESECTION OF THE PROSTATE USING A MODIFIED ELECTRO-VAPORIZING LOOP AND TRANSURETHRAL LASER VAPORIZATION OF THE PROSTATE, The Journal of urology, 154(5), 1995, pp. 1785-1790
Purpose: We determined the relative efficacy of a modification of tran
surethral resection of the prostate using a vaporizing loop (VaporTrod
e) with transurethral laser vaporization of the prostate using the Ul
traline dagger fiber. Materials and Methods: A comparative trial of 58
patients with symptomatic prostatism was performed. Parameters evalua
ted included operative time, postoperative catheterization time, Ameri
can Urological Association (AUA) symptom score, peak urine flow and po
st-void residual urine. Results: Of the 29 patients who underwent elec
tro-vaporization AUA symptom score decreased from 15.3 to 5.3 and 4.9,
and peak urine flow increased from 8.2 to 14.9 ml. per second and 15.
6 ml. per second at 1 and 3 months, respectively (p = 0.01). Of the 29
patients undergoing laser vaporization of the prostate AUA symptom sc
ore decreased from 14.7 to 10.1 and 7.6, and peak urine flow increased
from 9.7 to 13.7 ml. per second and 14.9 ml. per second at 1 and 3 mo
nths, respectively (p = 0.025). However, there were significant differ
ences in mean catheterization time (electro-vaporization group 14.7 ho
urs and laser group 79.6 hours, p <0.001), and cases of postoperative
irritative symptoms (3 electro-vaporization and 19 laser) and retentio
n requiring repeat catheterization (6 laser). Conclusions: Our early c
linical experience highlights several potential advantages of electro-
vaporization, particularly the low incidence of postoperative morbidit
y. Currently a multicenter clinical trial is underway to determine the
long-term efficacy and safety of electro-vaporization as a potential
therapeutic modality in the treatment of men with symptomatic benign p
rostatic hyperplasia.